Apogee Therapeutics, Inc. (APGE)
APGE Stock Price Chart
Explore Apogee Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze APGE price movements and trends.
APGE Company Profile
Discover essential business fundamentals and corporate details for Apogee Therapeutics, Inc. (APGE) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
14 Jul 2023
Employees
196.00
CEO
Michael Thomas Henderson
Description
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.
APGE Financial Timeline
Browse a chronological timeline of Apogee Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 10 Aug 2026
EPS estimate is -$1.10, while revenue estimate is $10.00m.
Earnings released on 11 May 2026
EPS came in at -$1.06 surpassing the estimated -$1.07 by +0.93%.
Earnings released on 2 Mar 2026
EPS came in at -$1.03 surpassing the estimated -$1.05 by +1.90%.
Earnings released on 10 Nov 2025
EPS came in at -$1.11 surpassing the estimated -$1.12 by +0.89%.
Earnings released on 11 Aug 2025
EPS came in at -$1.13 falling short of the estimated -$1.03 by -9.71%.
Earnings released on 12 May 2025
EPS came in at -$0.95 surpassing the estimated -$1.19 by +20.17%.
Earnings released on 3 Mar 2025
EPS came in at -$1.19 falling short of the estimated -$0.94 by -26.60%.
Earnings released on 12 Nov 2024
EPS came in at -$0.86 surpassing the estimated -$0.88 by +2.16%.
Earnings released on 12 Aug 2024
EPS came in at -$0.60 surpassing the estimated -$0.64 by +6.25%.
Earnings released on 13 May 2024
EPS came in at -$0.64 falling short of the estimated -$0.60 by -6.67%.
Earnings released on 5 Mar 2024
EPS came in at -$0.32 surpassing the estimated -$0.45 by +28.89%.
Earnings released on 13 Nov 2023
EPS came in at -$0.51 falling short of the estimated -$0.38 by -34.21%.
Earnings released on 17 Jul 2023
EPS came in at -$3.78 falling short of the estimated -$1.70 by -122.35%.
Earnings released on 31 Mar 2023
EPS came in at -$0.25 .
Earnings released on 31 Dec 2022
EPS came in at -$0.28 .
Earnings released on 30 Sept 2022
EPS came in at -$0.39 .
Earnings released on 30 Jun 2022
EPS came in at -$0.04 .
Earnings released on 31 Mar 2022
EPS came in at -$0.08 .
APGE Stock Performance
Access detailed APGE performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
